Lates News

Lilly China announced that Mufangda (Irtoboglutide injection) has been approved by the China National Medical Products Administration for use in adults with type 2 diabetes (T2DM) as monotherapy. This approval was based on the SURPASS-CN-MONO study specifically designed for early-stage T2DM patients in China. The results showed that after 40 weeks of treatment with Irtoboglutide as monotherapy, patients demonstrated clinically significant improvements in blood sugar control and weight loss without increasing the risk of hypoglycemia.